Treatment costs of directly observed therapy and traditional therapy for Mycobacterium tuberculosis: A comparative analysis

International Journal of Tuberculosis and Lung Disease

Volumn 3, Issue 11, 1999, Pages 976-984

  Weis, Stephen E ^a,b   Foresman, B ^a   Matty, K J ^a   Brown, A ^a   Blais, F X ^a   Burgess, G ^c   King, B ^c   Cook, P E ^c   Slocum, P C ^a  

^a UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER   (United States)

^b TEXAS DEPARTMENT OF STATE HEALTH SERVICES   (United States)

^c NONE

Author keywords

Cost; DOT; Relapse; Resistance; Tuberculosis

Indexed keywords

ISONIAZID; PYRAZINAMIDE; RIFAMPICIN;

ADOLESCENT; ADULT; ARTICLE; BACTERIUM CULTURE; DRUG COST; FEMALE; HEALTH CARE COST; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MYCOBACTERIUM TUBERCULOSIS; OUTPATIENT CARE; PATIENT COMPLIANCE; PRIORITY JOURNAL; RELAPSE; THORAX RADIOGRAPHY; TUBERCULOSIS;

ADOLESCENT; ADULT; AMBULATORY CARE; CHILD; COST OF ILLNESS; FEMALE; HEALTH CARE COSTS; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; PATIENT COMPLIANCE; PUBLIC HEALTH ADMINISTRATION; RETROSPECTIVE STUDIES; TEXAS; TUBERCULOSIS, PULMONARY;

EID: 0032757907     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Cohn D L, Catlin B J, Peterson K L, Judson F N, Sbarboro J A. A 62-dose 6-month therapy for pulmonary and extra-pulmonary tuberculosis: a twice-weekly, directly observed, and cost effective regimen. Ann Intern Med 1990; 112: 407-415.
2. Hong Kong Chest Service/British Medical Research Council. Controlled trial of 2, 4, and 6 months of pyrazinamide in 6-month, three times weekly regimens for smear-positive pulmonary tuberculosis, including an assessment of a combined preparation of isoniazid, rifampin and pyrazinamide: results at 30 months. Am Rev Respir Dis 1991; 143: 700-706.
3. Datta M, Radhamani M P, Selvaraj R, et al. Critical assessment of smear-positive pulmonary tuberculosis patients after chemotherapy under the district tuberculosis program. Tubercle 1993; 74: 180-186.
4. Brudney K, Dobkin J. Resurgent tuberculosis in New York City: human immunodeficiency virus, homelessness, and the decline of tuberculosis control programs. Am Rev Respir Dis 1991; 144: 745-749.
5. Block A B, Reider H L, Kelly G D, Cauthen G M, Hayden C H, Snider D E. The epidemiology of tuberculosis in the United States: implications for diagnosis and treatment. Clin Chest Med 1989; 10: 297-313.
6. Cantwell M F, Snider D E, Cauthen G M, Onorato I M. Epidemiology of tuberculosis in the United States, 1985 through 1992. JAMA 1994; 272: 535-539.
7. Zhang L X, Kan G Q, Wu J C, Liu C W, Dai Y S, Sun F X. The control of chronic infectious patients with pulmonary tuberculosis in a rural area of China. Tubercle 1989; 70: 21-25.
8. Weis S E, Slocum P C, Blais F X, et al. The effect of directly observed therapy on the rates of drug resistance and relapse in tuberculosis. N Engl J Med 1994; 330: 1179-1184.
9. Frieden T R, Fujiwara P I, Washko R M, Hamburg M A. Tuberculosis in New York City - turning the tide. N Engl J Med 1995; 333: 229-233.
10. Westaway M S, Conradie P W, Remmers L. Supervised outpatient treatment of tuberculosis: evaluation of a South African rural program. Tubercle 1991; 72: 140-144.
11. McDonald R J, Memon A M, Reichman L B. Successful supervised ambulatory management of tuberculosis treatment failures. Ann Intern Med 1982; 96: 297-302.
12. Centers for Disease Control and Prevention. Reported tuberculosis in the United States, 1997. Atlanta, GA: CDC, July 1998: p 36.
13. Controversies in pulmonary medicine. Am Rev Respir Dis 1988; 138: 1070-1077.
14. Moore R D, Chaulk C P, Griffiths R, Cavalcante S, Chaisson R E. Cost-Effectiveness of directly observed versus self-administered therapy for tuberculosis. Am J Respir Crit Care Med 1996; 154: 1013-1019.
15. Burman W J, Dalton C B, Med T B, Cohn D L, Butler J R G, Reves R R. A cost effectiveness analysis of directly observed therapy versus self-administered therapy for treatment of tuberculosis. Chest 1997; 112: 63-70.
16. CDC. Self-study modules on tuberculosis: treatment of tuberculosis infection and disease. Atlanta, GA: CDC, 1995: 1-56.
17. CDC. Outbreak of multidrug-resistant tuberculosis - Texas, California, and Pennsylvania. Morb Mortal Wkly Rep 1990; 39: 369-372.
18. O'Brien R J. The treatment of tuberculosis. In: Reichman L B, Hershfield E S, eds. Tuberculosis: a comprehensive international approach. Vol 66. Lung biology in health and disease. New York: Marcel Dekker, 1993: 207-240.
19. Brown R E, Miller B, Taylor W R, et al. Health care expenditures for tuberculosis in the United States. Arch Intern Med 1995; 155: 1595-1600.
20. Rosenblum L S, Castro K G, Dooley S, Morgan M. Effect of HIV infection and tuberculosis on hospitalizations and cost of care for young adults in the United States, 1985 to 1990. Ann Intern Med 1994; 121: 786-792.
21. Arno P S, Murray C J L, Bonuck K A, Alcaves P. The economicimpact of tuberculosis in hospitals in New York City: a preliminary analysis. J Law Med Ethics 1993; 21: 317-323.